SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 436 participants.

Also called NCT07445789

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 436 participants (planned count) (from the registry)
Sponsor
Martini Hospital Groningen (from the registry)
Registry
  • NCT NCT07445789
  • EU CT 2025-524245-27-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07445789. Randomized; quadruple masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2029-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation
Acronym
SMART-VERAPAF
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
Verapamil 240 mg slow-release tablet
Intervention (Drug)
metoprolol 100 mg slow-release tablet
Lead sponsor
Martini Hospital Groningen (class: other)

Record details

Record id
cardio:ct-nct07445789
Content hash
7672975258b7a651327d785bdc2213777f79d67ddf2ad227a2ad95e1dff4baf5